Recombinant Proteins iso9001 ISO13485
搜索
 >  生物标记素蛋白>Integrin alpha V beta 6 >IT6-H82E4

Biotinylated Human Integrin alpha V beta 6 (ITGAV&ITGB6) Heterodimer Protein, His,Avitag™&Tag Free

分子别名(Synonym)

Integrin alpha V beta 6,ITGAV&ITGB6

表达区间及表达系统(Source)

Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free (IT6-H82E4) is expressed from human 293 cells (HEK293). It contains AA Phe 31 - Val 992 (ITGAV) & Gly 22 - Asn 707 (ITGB6) (Accession # NP_002201.1 (ITGAV)& AAI21179.1~ITGB6)).

Predicted N-terminus: Phe 31 (ITGAV) & Gly 22 (ITGB6)

蛋白结构(Molecular Characterization)

Online(Phe 31 - Val 992 (ITGAV) & Gly 22 - Asn 707 (ITGB6)) NP_002201.1 (ITGAV)& AAI21179.1 (ITGB6)

Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free, produced by co-expression of ITGAV and ITGB6, has a calculated MW of 114.7 kDa (ITGAV) and 79.6 kDa (ITGB6). Subunit ITGAV is fused with an acidic tail at the C-terminus and followed by a polyhistidine tag and an Avi tag (Avitag™) and subunit ITGB6 contains no tag but a basic tail at the C-terminus. The predicted N-terminus is Phe 31 (ITGAV) & Gly 22 (ITGB6). The non-reducing (NR) protein migrates as 135-150 kDa (ITGAV) and 85-100 kDa (ITGB6) respectively due to glycosylation.

标记(Biotinylation)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by reduced SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT6-H82E4) SDS-PAGE gel

Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free on SDS-PAGE under non-reducing (NR) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

 

活性(Bioactivity)-ELISA

Biotinylated Human ELISA

Immobilized Human TGFB1, His Tag (Cat. No. TG1-H524x) at 5 μg/mL (100 μL/well) can bind Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT6-H82E4) with a linear range of 2-10 ng/mL (QC tested).

Protocol

Biotinylated Human SPR

Immobilized Fibronectin at 10 μg/mL (100 μL/well) can bind Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT6-H82E4) with a linear range of 0.08-1.25 μg/mL (Routinely tested).

Protocol

背景(Background)

Integrin alpha V beta 6 is a heterodimer of beta-6 associating with alpha-V. Integrin alpha-V beta-6 is a receptor for fibronectin and cytotactin. It recognizes the sequence R-G-D in its ligands. Internalisation of integrin alpha-V beta-6 via clathrin-mediated endocytosis promotes carcinoma cell invasion. Also, Integrin alpha-V beta-6 acts as a receptor for coxsackievirus A9 and coxsackievirus B1 as well as herpes simplex virus-1/HHV-1. Furthermore, it binds the TGF-beta latency‑associated peptide (LAP) and activates TGF-beta 1 or TGF-beta 3 from large latent complexes. This activation requires interaction with LTBP-1 and fibronectin, and is enhanced by PAR-1.

 

前沿进展

 
货号/价格
开发建议
文档
联系电话:
400-682-2521(全国)
010-57737274(北京)
021-26136428(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
techsupport@acrobiosystems.com
Integrin alpha V beta 6靶点信息
英文全称:Integrin alpha-V/beta-6
中文全称:整合素α-V/β-6复合体
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:4详情
最高研发阶段:临床二期
查看更多信息
推荐会议
查看全部会议

消息提示

请输入您的联系方式,再点击提交!

确定